Agilent Technologies Collaborating With Weill Cornell Medical College to Advance Research in ALS
August 26 2015 - 11:00AM
Business Wire
Agilent Technologies Inc. (NYSE: A) today announced it is
collaborating with Dr. Steven Gross, a faculty member in the
Department of Pharmacology at Weill Cornell Medical College, in New
York, N.Y., to advance research in amyotrophic lateral sclerosis,
also known as Lou Gehrig’s disease. Agilent will provide the latest
mass spectrometry technology to support his research, working
toward an understanding of how the most common form of this disease
develops in the body.
The Agilent 6230B LC TOF and 6550A LC Q-TOF mass spectrometers
will be housed in the laboratory of Dr. Gross, an internationally
recognized expert in the use of mass spectrometry-based
metabolomics. His expertise is in pharmacology and cell biology,
particularly in relation to the role of nitric oxide as a signaling
molecule.
Dr. Gross, along with Dr. Qiuying Chen, an assistant research
professor of pharmacology at Weill Cornell, and Ben Schwartz, a
student in the pharmacology doctoral program at Weill Cornell
Graduate School of Medical Sciences, is studying the most common
form of ALS. ALS is a deadly and progressive neurodegenerative
disease that affects nerve cells in the brain and spinal cord, and
is also characterized by impaired metabolic control.
Sporadic amyotrophic lateral sclerosis (sALS) accounts for about
90 percent of all ALS cases and has no obvious genetic driver. Dr.
Gross and his collaborators—Dr. Giovanni Manfredi, a professor of
neuroscience in the Feil Family Brain and Mind Research Institute
at Weill Cornell, and Dr. Lorenz Studer, director of Sloan
Kettering Institute’s Center for Stem Cell Biology—are
investigating the molecular underpinnings of this form of ALS. The
Agilent tools will empower the investigators to apply a
multi-disciplinary-based approach to understanding the roots of
this disease. Accurate-mass mass spectrometry will enable these
researchers to test the hypothesis that fibroblasts express
systemic metabolic markers that inform ALS.
“Translational research using a combination of biological
disciplines—genomics, proteomics, transcriptomics, metabolomics—is
an emerging trend in academia,” said Steven Fischer, market
director for life science research in academia and government at
Agilent. “Most researchers, however, do not know how to perform
multi-omic analysis, and successful examples are needed. Agilent is
working with the Gross lab at Weill Cornell to advance the
multi-omics-based approach to disease research, using sporadic ALS
to demonstrate the power of this method.”
“We’re very excited to ally ourselves with Agilent to extend our
planned attack on the sporadic form of ALS,” Dr. Gross said. “Our
newly established scientific collaboration offers a rare
opportunity to obtain and integrate multi-omics data, with the
potential to yield an unprecedented understanding of the molecular
basis for this devastating disease. We anticipate that this
scientific work with Agilent will continue into the future as we
apply multi-omics approaches to other poorly understood diseases
with unmet clinical needs.”
Agilent is a leader in mass spectrometry and offers
comprehensive solutions across all the major omics disciplines.
Agilent solutions cover sample preparation, instrumentation and
software to process and analyze research data in order to gain
biological insights into complex diseases.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in
life sciences, diagnostics, and applied chemical markets, is the
premier laboratory partner for a better world. Agilent works with
customers in more than 100 countries, providing instruments,
software, services, and consumables for the entire laboratory
workflow. The company generated revenues of $4.0 billion in fiscal
2014 and employs about 12,000 people worldwide. Agilent marks its
50th anniversary in analytical instrumentation this year.
Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150826005082/en/
EDITORIAL CONTACT:Agilent Technologies Inc.Victoria
Wadsworth-Hansen, +45 2933
6980victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024